drugset / Trial / NCT01512277
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
Phase 1
Completed
24 enrolled
University Hospital, Lille
Institut National de la Santé Et de la Recherche Médicale, France · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this clinical study is to evaluate safety and immunogenicity in adult healthy volunteers of the vaccine candidate against schistosomiasis named Bilhvax.
Timeline
- Start
- 1998-09
- Primary completion
- 1999-03
- Completion
- 1999-09
Publications
- Background Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol. 2005 Mar;21(3):143-9. doi: 10.1016/j.pt.2005.01.003.
- Background Capron A, Riveau GJ, Bartley PB, McManus DP. Prospects for a schistosome vaccine. Curr Drug Targets Immune Endocr Metabol Disord. 2002 Oct;2(3):281-90. doi: 10.2174/1568008023340587.
- Background Capron A, Capron M, Riveau G. Vaccine development against schistosomiasis from concepts to clinical trials. Br Med Bull. 2002;62:139-48. doi: 10.1093/bmb/62.1.139.
- Results Riveau G, Deplanque D, Remoue F, Schacht AM, Vodougnon H, Capron M, Thiry M, Martial J, Libersa C, Capron A. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis. 2012;6(7):e1704. doi: 10.1371/journal.pntd.0001704. Epub 2012 Jul 3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rSh28GST | Vaccine | 100 ug | Subcutaneous |
| Subject | rSh28GST | Vaccine | 300 ug | Subcutaneous |